baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

MEDICENNA THERAPEUTICS CORP/ CA58490H1073 /

2024-05-27 9:57:59 PM	Chg. +0.08	Volume	Bid10:00:09 AM	Ask10:00:09 AM	High	Low
2.44CAD	+3.39%	28,726 Turnover: 67,849	2.30Bid Size: 5,000	2.44Ask Size: 2,100	2.44	2.35

GlobeNewswire 05-22 Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...

GlobeNewswire 05-13 Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

GlobeNewswire 04-24 Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ...

GlobeNewswire 04-10 Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation a...

GlobeNewswire 04-09 Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation a...

GlobeNewswire 04-09 Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-fun...

GlobeNewswire 04-04 Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire 03-06 Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Associat...

GlobeNewswire 02-14 Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

GlobeNewswire 02-13 Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (...

GlobeNewswire 01-12 Medicenna Announces Appointment of New Auditor

GlobeNewswire 01-09 Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

GlobeNewswire 2023-12-19 Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

GlobeNewswire 2023-11-17 Delisting of Securities of Genesis Growth Tech Acquisition Corp.; Financial Strategies Acquisition C...

GlobeNewswire 2023-11-17 Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Gliob...

GlobeNewswire 2023-11-14 Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highligh...

GlobeNewswire 2023-11-09 Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at...

GlobeNewswire 2023-11-06 Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILIT...

GlobeNewswire 2023-11-03 Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-...

GlobeNewswire 2023-10-27 Medicenna Announces Nasdaq Delisting and Cutback of Management Team

GlobeNewswire 2023-10-25 Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABIL...

GlobeNewswire 2023-10-24 Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Can...

GlobeNewswire 2023-10-10 Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

GlobeNewswire 2023-10-03 Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunolog...

GlobeNewswire 2023-09-28 Medicenna Announces Results of Annual and Special Meeting of Shareholders

MEDICENNA THERAPEUTICS CORP/ CA58490H1073 /

If you wish to receive reply to your feedback, please provide your email address.